Diagnosis and Complication Risk Assessment of Pancreatic Diabetes within Normal Value Ranges of Leuc
This patent can use for daily complication risk Assessment of all diabetic patients and save lifes, suffering from the diabetic complications at all around the world. it is more important method than Hemoglobin A1c. Because all diabetic complications can monitorizing using one marker (procalcitonin) in 24 hours period. New technology of insulin pump system or traditional diabetes mellitus therapy need this invention for proper diabetic complication (retinopathy, nephropathy,neuropathy) treatment
This method use rapid or Automatic test device for procalcitonin blood levels
License agreement
Inventor: Chonge Chen | Cleph. Sturt. Keklam | chuxian Wu
Priority Number: CN100572554C
IPC Current: C12Q000168
Assignee Applicant: The Chinese University of Hong Kong
Title: Risk estimution for diabetic to suffer from diabetic renopathy or blood-lipid imbalance | Evaluation diabetes patients suffer from diabetic nephropathy, or dyslipidemia disorder risk of
Usefulness: Risk estimution for diabetic to suffer from diabetic renopathy or blood-lipid imbalance | Evaluation diabetes patients suffer from diabetic nephropathy, or dyslipidemia disorder risk of
Novelty: Risk estimation for diabetic to suffer from diabetic renopathy or blood-lipid imbalance
Disease Diagnostic/Treatment
Other Disease
EP20120154587
EPO designated contracting states
Status: Patent Application
Price: negotiable
Turkiye
